Introduction {#jcmm13468-sec-0001}
============

Over the last three decades, the enormous progress in cell processing technology has enhanced a general shift from heterologous to autologous stem cell‐based therapies. In the prospect of having biomaterials and bioactive surgical additives with predictable outcome in regenerative medicine, several techniques have been developed to process peripheral blood and to obtain products useful for controlling inflammation and enforcing the physiological events of haemostasis and wound healing [1](#jcmm13468-bib-0001){ref-type="ref"}, [2](#jcmm13468-bib-0002){ref-type="ref"}, [3](#jcmm13468-bib-0003){ref-type="ref"}, [4](#jcmm13468-bib-0004){ref-type="ref"}. Depending on their contents of platelets, leucocytes and fibrin architecture, they are commonly classified into four families: (*i*) pure platelet‐rich plasma (P‐PRP, in liquid or gel form); (*ii*) leucocyte‐ and platelet‐rich plasma (L‐PRP, in liquid or gel form); (*iii*) pure platelet‐rich fibrin (P‐PRF); and (*iv*) leucocyte‐ and platelet‐rich fibrin (L‐PRF) [5](#jcmm13468-bib-0005){ref-type="ref"}. Among them, L‐PRF offers overall higher amounts of released TGF‐β1, a sustained, long‐term release of growth factors (VEGF, IGF1, PDGF‐AB) and cytokines (IL‐1β), and stronger induction of cell migration *in vitro* [6](#jcmm13468-bib-0006){ref-type="ref"}. Obtained by different production methods and devices, the haemoderivatives demonstrate to be beneficial for tissues with restricted blood supply, slow cell turnover, limited extracellular matrix restoration facilitating the recruitment, proliferation and maturation of cells participating in regeneration. They are commonly used in clinics for numerous medical applications including (*i*) the healing of recalcitrant ulcers and burns; (*ii*) the stimulation of tissue regeneration in dentistry, implantology, and maxillofacial and plastic surgery; (*iii*) the treatment of knee osteoarthritis; and (*iv*) the repair of musculoskeletal tissue, tendon, and ligament lesions [1](#jcmm13468-bib-0001){ref-type="ref"}, [7](#jcmm13468-bib-0007){ref-type="ref"}, [8](#jcmm13468-bib-0008){ref-type="ref"}. To date, the intrinsic regenerative potentialities of L‐PRP have been commonly attributed to platelet‐ and leucocyte‐derived factors (coagulation factors, growth factors and cytokines) and fibrin matrix that synergistically orchestrate the recruitment of stem cells or progenitor cells following an inflammatory response driven by neutrophils, M1‐polarized macrophages and T lymphocytes (early‐phase), and M2 macrophages (late‐phase) [9](#jcmm13468-bib-0009){ref-type="ref"}. A growing body of evidence demonstrates that the contribution of L‐PRF to *in vivo* angiogenesis and vasculogenesis at injury site is mediated by intrinsically carried haematopoietic stem cells (HSCs) (CD34^+^) and endothelial progenitor cells (EPCs) (CD34^+^/VEGR‐2^+^/CD133^+^) [10](#jcmm13468-bib-0010){ref-type="ref"}. Although fibroblast‐like multipotent cells with proliferative and multidifferentiative properties have been identified in human peripheral blood [11](#jcmm13468-bib-0011){ref-type="ref"}, [12](#jcmm13468-bib-0012){ref-type="ref"}, [13](#jcmm13468-bib-0013){ref-type="ref"}, to date, no evidence about their presence has been reported in L‐PRF products. As the discovery of multipotent stem cells in L‐PRF products could have important implications for the future of regenerative medicine confirming (*i*) the active role of the haemoderivatives in the so‐called *in vivo* guided regeneration and (*ii*) the development of a standardized method to extract autologous stem cells, in this study, a leucocyte--platelet‐concentrated membrane, prepared according to the Caloprisco protocol [10](#jcmm13468-bib-0010){ref-type="ref"} and called CLP‐MB, has been cultured *in vitro* to characterize the stemness grade of sprouted cells under permissive conditions.

Materials and methods {#jcmm13468-sec-0002}
=====================

Haemoderivatives {#jcmm13468-sec-0003}
----------------

Following the Italian standards of quality assurance, leucocyte‐ and platelet‐rich fibrin membranes (CLP‐MB) were prepared at the Immunohematology and Transfusion Medicine Department, San Martino Hospital of Belluno, Italy. Under Italian ethic committee authorization and informed consent, ten male volunteer donors were submitted to a multicomponent apheresis procedure, and blood samples were processed according to the procedure published by Caloprisco *et al*. [10](#jcmm13468-bib-0010){ref-type="ref"}. In Table [1](#jcmm13468-tbl-0001){ref-type="table-wrap"}, haematologic values of blood samples and blood derivatives are reported.

###### 

Haematologic values of blood samples before apheresis (pre‐AP) and at final phase of concentrated leucocyte/platelet membrane (CPL‐MB)

  --------------------------------------------------------------------------------------------------------------------------------
  Patient   Phase         RBC (×10^6^/μl)   PLT (×10^3^/μl)   WBC (×10^3^/μl)   NE (×10^3^/μl)   LY (×10^3^/μl)   MO (×10^3^/μl)
  --------- ------------- ----------------- ----------------- ----------------- ---------------- ---------------- ----------------
  1         pre‐AP\       5.23\             183\              6.58\             4.70\            1.10\            0.60\
            **CLP‐MB**    **0.58**          **1452**          **22.40**         **4.85**         **9.22**         **10.17**

  2         pre‐AP\       4.46\             249\              6.27\             4.40\            1.40\            0.30\
            **CLP‐MB**    0.37              1511              23.20             2.80             16.00            3.60

  3         **pre‐AP**\   5.53\             184\              4.36\             2.70\            1.30\            0.30\
            **CLP‐MB**    **0.37**          **1464**          **17.60**         **0.80**         **12.80**        **4.00**

  4         **pre‐AP**\   5.40\             185\              6.38\             3.20\            1.90\            0.60\
            **CLP‐MB**    **0.39**          **1700**          **30.00**         **0.80**         **21.20**        **8.00**

  5         pre‐AP\       4.18\             206\              4.66\             2.90\            1.10\            0.30\
            **CLP‐MB**    **0.30**          **1800**          **18.00**         **1.20**         **12.40**        **4.00**

  6         pre‐AP\       4.96\             171\              4.26\             2.30\            1.50\            0.30\
            **CLP‐MB**    **0.53**          **1801**          **29.40**         **2.70**         **20.30**        **6.20**

  7         pre‐AP\       4.87\             153\              3.47\             1.60\            1.40\            0.40\
            **CLP‐MB**    **1.06**          1502              30.80             1.60             22.30            6.90

  8         pre‐AP\       5.13\             188\              3.12\             1.60\            1.00\            0.40\
            **CLP‐MB**    **0.55**          **1808**          **21.00**         **1.20**         **13.30**        **6.50**

  9         pre‐AP\       5.33\             234\              4.04\             1.60\            1.6\             0.50\
            **CLP‐MB**    **0.64**          **1508**          **25.20**         **3.20**         **15.40**        **6.60**

  10        pre‐AP\       4.33\             199\              4.58\             2.10\            1.80\            0.50\
            **CLP‐MB**    **0.28**          **1794**          **23.25**         **0.60**         **17.10**        **5.55**
  --------------------------------------------------------------------------------------------------------------------------------

RBC: red blood cells; PTL: platelets; WBC: total leucocytes; NE: neutrophils; LY: lymphocytes; MO: monocytes. The representative data of RBC, PLT and leucocytes from CPL‐MB are reported in bold.
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Isolation of fibroblast stem‐like cells {#jcmm13468-sec-0004}
---------------------------------------

Rounded patches of CPL‐MB were prepared and seeded in polystyrene culture dishes (BD, Franklin Lakes, NJ, USA) preconditioned with foetal bovine serum (Invitrogen‐Thermo Fisher Scientific, Waltham, MA, USA). Thus, samples were maintained at 37°C, 95% humidity and 5% CO~2~, in proliferation culture medium \[Alpha‐modified Eagle\'s medium (α‐MEM) without nucleosides, 50% foetal bovine serum, 1% antibiotic solution, 1% Glutamax (all from Invitrogen Thermo Fisher Scientific, Inc)\]. When cell sprouting was observed, CPL‐MB patches were discarded, and culture medium was changed with fresh one every 2 days. Cell expansion was performed for 21 days before detecting fibroblastoid cells (CPL‐CMCs) with proliferative potential. At 80% confluence, CPL‐CMC cells were detached using 0.02% EDTA/0.25% trypsin solution, and subcultures were seeded (5 × 10^3^ cells/cm^2^) in proliferation culture medium containing 16.5% FBS. In alternative to commercial FBS, autologous serum has been suggested to be used in the perspective of clinical use of CPL‐CMCs. During cell isolation and expansion phases, the samples were daily observed by optical microscope DM/IL (Leica, Wetzlar, Germany), and pictures were taken with Nikon Digital Sight Ds‐SMCc camera (Nikon Corporation, Tokyo, Japan). In order to correlate the activation of circulating multipotent cells to the inflammatory environment promoted by haemoderivatives, the expression of TNFα, IL‐10, Wnt3a, TGFβ1, CD206 was investigated by Western blot in cells sprouted from CPL‐MB. In parallel, the expression pattern of CPL‐MB was used as a reference.

Proteomic analysis of CPL‐derived adherent cells {#jcmm13468-sec-0005}
------------------------------------------------

Using antibodies reported in Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"}, Western blot analysis was performed on total protein extract of CLP membranes and cells isolated from early (inflammatory cells) and late (CLP‐CMCs) sprouted populations. The protein extraction was carried out using a RIPA buffer containing 0.25% TWEEN^®^20 (Sigma‐Aldrich, St. Louis, MO, USA). After quantification using BCA Protein Assay Reagent Kit (Thermo Fisher Scientific, Inc.), 20 μg of total protein extracts from each sample was separated by reducing SDS‐PAGE (Bio‐Rad Laboratories Inc., Hercules, CA, USA) and then electrophoretically transferred to 0.45‐μm nitrocellulose membrane (Immunological Sciences, Rome, Italy). The immunoblot was performed by incubating samples overnight at 4°C with primary antibodies against CD206, TGFβ1, Wnt3a, IL‐10, TNFα (Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"}). After washing with 0.25% TWEEN^®^20 in PBS, the membranes were treated for 1 h with peroxidase‐conjugated secondary goat antimouse and anti‐rabbit antibodies (Immunological Sciences) and then developed using enhanced chemiluminescence substrate (Immunological Sciences). The immunoreactive sites were visualized using VersaDoc Imaging System (Bio‐Rad Laboratories Inc.). The protein expression level was normalized to glyceraldehyde 3‐phosphate dehydrogenase/GAPDH housekeeping protein (EMD Millipore, Billerica, MA, USA) and quantified by ImageLab processing software (Bio‐Rad Laboratories Inc.). Data from three independent experiments were reported as a ratio within the target protein and relative housekeeping protein expression.

###### 

Antibodies used for flow cytometry analysis, Western blot and immunofluorescence

  Primary antibodies                         Manufacturing company
  ------------------------------------------ ------------------------------
  FITC mouse anti‐human CD11c                BD Biosciences
  APC mouse anti‐human CD13                  BD Biosciences
  PE mouse anti‐human CD14                   Santa Cruz Biotecnology, Inc
  FITC mouse anti‐human CD29                 Santa Cruz Biotecnology, Inc
  PE mouse anti‐human CD31                   BD Biosciences
  PE‐Cy5 mouse anti‐human CD33               BD Biosciences
  PE‐Cy7 mouse anti‐human CD34               BD Biosciences
  Rabbit anti‐human CD38                     Santa Cruz Biotecnology, Inc
  PE mouse anti‐human CD40                   BD Biosciences
  PE mouse anti‐human CD44                   Santa Cruz Biotecnology, Inc
  PE mouse anti‐human CD45                   Santa Cruz Biotecnology, Inc
  FITC mouse anti‐human CD49f                ImmunoTools
  PE mouse anti‐human CD73                   BioLegend, Inc
  PE‐Cy5 mouse anti‐human CD80               BD Biosciences
  APC mouse anti‐human CD86                  BD Biosciences
  FITC mouse anti‐human CD90                 Santa Cruz Biotecnology, Inc
  Mouse anti‐human CD103                     Santa Cruz Biotecnology, Inc
  PE mouse anti‐human CD105                  Santa Cruz Biotecnology, Inc
  FITC mouse anti‐human CD106                Acris Antibodies GmbH
  APC mouse anti‐human CD133/1               Miltenyi Biotec
  PE mouse anti‐human CD133/2                Miltenyi Biotec
  FITC mouse anti‐human CD146                Santa Cruz Biotecnology, Inc
  FITC mouse anti‐human CD166                Santa Cruz Biotecnology, Inc
  Rabbit anti‐human CD206                    Santa Cruz Biotecnology, Inc
  PE mouse anti‐human PDGFRβ                 BD Biosciences
  FITC mouse anti‐human VEGFR2               R&D Systems, Inc.
  Rabbit anti‐human FGFR1                    Santa Cruz Biotecnology, Inc
  APC mouse anti‐human FGFR2                 R&D Systems, Inc.
  Rabbit anti‐human EGFR                     Santa Cruz Biotecnology, Inc
  FITC mouse anti‐human NG2                  Santa Cruz Biotecnology, Inc
  Rabbit anti‐human VE‐cadherin              Santa Cruz Biotecnology, Inc
  Mouse anti‐human αSMA                      EMD Millipore
  Mouse anti‐human vimentin                  Santa Cruz Biotecnology, Inc
  Rabbit anti‐human vWF                      Abcam
  Mouse anti‐human FVIII                     Abcam
  Rabbit anti‐human TGFβ1                    Santa Cruz Biotecnology, Inc
  Rabbit anti‐human Wnt3a                    Immunological Sciences
  Rabbit anti‐human IL‐10                    Immunological Sciences
  Rabbit Anti‐human TNFα                     Immunological Sciences
  PE mouse anti‐human CXCR4                  Santa Cruz Biotecnology, Inc
  Rabbit anti‐human Frizzled 1               Acris Antibodies GmbH
  PE mouse anti‐human Frizzled 2             Santa Cruz Biotecnology, Inc
  Goat anti‐human Frizzled 3                 Santa Cruz Biotecnology, Inc
  Goat anti‐human Frizzled 9                 Santa Cruz Biotecnology, Inc
  PE mouse anti‐human SEEA4                  BD Biosciences
  Alexa Fluor^®^ 488 mouse anti‐human TLR4   Bioss Antibodies
  Rabbit anti‐human SIRPα                    eBiosciences
  FITC mouse anti‐human GR‐1/Ly6G            BD Biosciences
  PE‐Cy7 mouse anti‐human HLA‐ABC            BD Biosciences
  PE‐Cy5 mouse anti‐human HLA DR             BD Biosciences

  **Secondary antibodies**       
  ------------------------------ ------------------------------
  PE goat antimouse              Santa Cruz Biotecnology, Inc
  PE goat anti‐rabbit            Santa Cruz Biotecnology, Inc
  PE donkey anti‐goat            Santa Cruz Biotecnology, Inc
  Alexa Fluor^®^ 488 antimouse   EMD Millipore

  **Isotype controls**                 
  ------------------------------------ -----------------------------------------------------------------------------------------------------
  FITC Isotype Control                 Santa Cruz Biotechnology, Inc; BD Biosciences; ImmunoTools; Acris Antibodies GmbH; R&D Systems, Inc
  PE Isotype Control                   Santa Cruz Biotechnology, Inc; BD Biosciences; BioLegend, Inc; Miltenyi Biotec
  PE‐Cy5 Isotype Control               BD Biosciences
  PE‐Cy7 Isotype Control               BD Biosciences
  APC Isotype Control                  R&D Systems, Inc.; Miltenyi Biotec.
  Alexa Fluor^®^ 488 Isotype Control   Bioss Antibodies
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Proliferation capacity of CPL‐CMCs {#jcmm13468-sec-0006}
----------------------------------

The proliferation rate of CPL‐CMCs was evaluated culturing for 16 consecutive passages and seeding in triplicate each generation at a density of 5 × 10^3^ cells/cm^2^. After 24 hrs, the cells were detached using EDTA/trypsin solution and counted with a hemocytometer. The average number of cells and standard deviation (SD) for each passage was used to define the doubling population time (DPT).

Stemness gene profile {#jcmm13468-sec-0007}
---------------------

The expression of OCT4, NANOG, SOX2, KLF4, NOTCH, STAT3 and REX1 was investigated by quantitative PCR (qPCR) in subcultures evolving from 4th generation to 20th generations, using oligonucleotides (Thermo Fisher Scientific, Inc.) listed in Table [3](#jcmm13468-tbl-0003){ref-type="table-wrap"}. Reverse transcription and amplification reaction were carried out using SensiFAST™ SYBR^®^ One‐Step kit (Bioline Inc., London, UK) and AriaMx Real‐time PCR System (Agilent Technology, Santa Clara, CA, USA). For statistical significance of data, three independent analyses of each target per subpopulation were performed preparing multiple technical replicates. The hypoxanthine phosphoribosyltransferase 1/HPRT1 housekeeping gene was considered as control. For quantification of gene expression level, the comparative CT method (2^−ΔCt^) was used.

###### 

Oligonucleotides used for RT‐PCR and qPCR analysis (F = forward; R = reverse)

  --------------------------------------------------------------------------------------
  Genes   Primer sequences                Accession                    Amplicon length
  ------- ------------------------------- ---------------------------- -----------------
  TGFA    F: CACACTCAGTTCTGCTTCCA\        [NM_003236.3](NM_003236.3)   151 bp
          R: GTGATGGCCTGCTTCTTCT                                       

  TGFB1   F: CGTGGAGCTGTACCAGAAATAC\      [NM_000660.6](NM_000660.6)   158 bp
          R: CTAAGGCGAAAGCCCTCAAT                                      

  LIF     F: TCTGCACTGGAAACATGGG\         [NM_002309.4](NM_002309.4)   104 bp
          R: CTGATCTGGTTCATGAGGTTGT                                    

  IL1A    F: AGTGAGACCAACCTCCTCTT\        [NM_000575.4](NM_000575.4)   108 bp
          R: ACACCCAGTAGTCTTGCTTTG                                     

  IL1B    F: ATGGACAAGCTGAGGAAGATG\       [NM_000576.2](NM_000576.2)   114 bp
          R: CCCATGTGTCGAAGAAGATAGG                                    

  IL4     F: CACCGAGTTGACCGTAACA\         [NM_000589.3](NM_000589.3)   138 bp
          R: CTTCCATGGTGGCTGTAGAA                                      

  IL6     F: GAGCTGTGCAGATGAGTACAA\       [NM_000600.4](NM_000600.4)   190 bp
          R: GGACTGCAGGAACTCCTTAAA                                     

  IL10    F: GCTGGAGGACTTTAAGGGTTAC\      [NM_000572.2](NM_000572.2)   105 bp
          R: GATGTCTGGGTCTTGGTTCTC                                     

  IL12    F: ATTCCAGAGAGACCTCTTTCATAAC\   [NM_000882.3](NM_000882.3)   124 bp
          R: CTTGAACTCCACCTGGTACATC                                    

  TNFA    F: CCAGGGACCTCTCTCTAATCA\       [FJ795028.1](FJ795028.1)     106 bp
          R: TCAGCTTGAGGGTTTGCTAC                                      

  TNFR1   F: GGACAGGGAGAAGAGAGATAGT\      [AH003016.2](AH003016.2)     115 bp
          R: TGGACAGTCATTGTACAAGTAGG                                   

  TNFR2   F: TGCATCGTGAACGTCTGTAG\        [NM_001066.2](NM_001066.2)   84 bp
          R: GGAATCTGTGTCTCCCATTGT                                     

  REX1    F: GAGATGGAGTAAGGAGGGAGAT\      [NM_174900.3](NM_174900.3)   105 bp
          R: ATGGACAAGCTGAGGAAGATG                                     

  SOX2    F: ATTCCAGAGAGACCTCTTTCATAAC\   [NM_003106.3](NM_003106.3)   191 bp
          R: TACCTTTCTGCCCGTGAAGTGGAT                                  

  STAT3   F: AAAGACAGCTACGTGGGTGACGAA\    [NM_213662.1](NM_213662.1)   175 bp
          R: AGAACCTGCAGGAGGCAGAAGAAT                                  

  NOTCH   F: AGGATCACACAGGTGGCCCATATT\    [NM_017617.3](NM_017617.3)   112 bp
          R: AGCTAAAGCAGCAGCAAACTTCGG                                  

  OCT4    F: TCGAGGAATTGCTCAAAGTGCTGG\    [NM_002701.4](NM_002701.4)   102 bp
          R: ACACCAACGGCTGGAAGCTAAATC                                  

  KLF4    F: GAAGATGCGCAGCAGCGAGAATTT\    [NM_004235.4](NM_004235.4)   106 bp
          R: ACTTTCTCCTGTCCGTCATTGGCT                                  

  NANOG   F: AGAATATGCACCAGGCCGAAGAGT\    [NM_024865.2](NM_024865.2)   106 bp
          R: AGCTAAGAGTCTTTGGTGCTGGCT                                  

  TUBβ3   F: ACAACGAGGCCTCTTCTCACAAGT\    [NM_006086.3](NM_006086.3)   225 bp
          R: ATACTCCTCACGCACCTTGCTGAT                                  

  vWF     F: ACTCAGTGCATTGGTGAGGATGGA\    [NM_000552.4](NM_000552.4)   842 bp
          R: TCGGACACACTCATTGATGAGGCA                                  

  CD31    F: ACTGGACAAGAAAGAGGCCATCCA\    [NM_000442.4](NM_000442.4)   677 bp
          R: TCCTTCTGGATGGTGAAGTTGGCT                                  

  HPRT1   F: ATGGACAGGACTGAACGTCTTGCT\    [NM_000194.2](NM_000194.2)   79 bp
          R: TTGAGCACACAGAGGGCTACAATG                                  
  --------------------------------------------------------------------------------------
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Immunophenotyping of CPL‐CMCs {#jcmm13468-sec-0008}
-----------------------------

Using anti‐human antibodies reported in Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"}, subcultures from 4th to 20th generations were analysed by flow cytometry (FCM) for the expression of typical markers related to stemness, lineage commitment, cell--ECM interactions and enzyme/signalling molecules. Flow cytometry analysis was performed with FACSCanto II Flow cytometer (BD Biosciences, CA, USA) and FACS Diva software (BD). Data were reported as mean percentage of positive cells and relative mean fluorescence intensity (MFI) calculated on *n* = 3 replicas of each sample for all target markers. Samples treated with only secondary antibodies or isotype control antibodies (Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"}) were prepared as references.

Differentiative plasticity of CPL‐CMCs {#jcmm13468-sec-0009}
--------------------------------------

CLP‐CMCs were seeded at 1.5 × 10^4^ cells/cm^2^ and induced to differentiate under the conditions described below. In parallel, cultures in proliferation medium were prepared as controls. After 7 and 14 days, the analysis by cytochemistry, immunofluorescence, PCR, WB and FCM was performed to confirm the lineage‐specific differentiation. In all experiments, resting cells were used as reference. Antibodies and oligonucleotides are reported in Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"} and Table [3](#jcmm13468-tbl-0003){ref-type="table-wrap"}, respectively. For gene expression analysis, the housekeeping HPRT1 was considered for normalization of data.

Adipogenic induction {#jcmm13468-sec-0010}
--------------------

The stimulation was performed with DMEM high‐glucose medium (Sigma‐Aldrich) supplemented with 10% FBS (Invitrogen‐Thermo Fisher Scientific, Inc), 1% antibiotic solution (Sigma‐Aldrich) and adipogenic supplements (1 mM dexamethasone, 0.5 mM 3‐isobutyl‐1‐methylxanthine, 10 mg/ml insulin, 60 mM indomethacin) (all from Sigma‐Aldrich). After 3, 7 and 14 days from induction, the adipogenic commitment was evaluated detecting the expression of perilipin/PLIN1 and leptin/LEP genes by qPCR. In parallel, samples were fixed with 10% formalin solution (Sigma‐Aldrich) and stained with Oil Red O solution (5 mg/ml in isopropanol) (Sigma‐Aldrich) to verify the presence of cytoplasmic lipid droplets. Nuclei were counterstained with haematoxylin (Sigma‐Aldrich) according to the standard procedure.

Myogenic induction {#jcmm13468-sec-0011}
------------------

Subconfluent (\~90%) CLP‐CMCs were grown in standard medium supplemented with 100 ng/ml IGF (ImmunoTools, Friesoythe, Germany) and 200 μM ascorbic acid (Sigma‐Aldrich Co.). At different time‐points (3, 7, 14 days), myogenic differentiation was verified by qPCR investigating the expression of genes related to early (myogenic differentiation 1/MYOD1), intermediate (myogenin/MYOG) and late (tropomyosin 1/TPM1) differentiation phases. At 14 days from induction, the expression of vimentin was evaluated by immunofluorescence to detect the formation of syncytium‐like structures.

Neurogenic induction {#jcmm13468-sec-0012}
--------------------

Neurogenic differentiation was induced in subconfluent (\~60%) cells using DMEM/F‐12 medium (Thermo Fisher Scientific, Inc.) supplemented with 2% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and 0.1% dimethyl sulphoxide (DMSO) (all from Sigma‐Aldrich). After 3 and 7 days, the samples were submitted to the analysis of brain‐derived neurotrophic factor/BDNF, nerve growth factor/NGF, tubulin beta 3 class III/TUBB3 and synaptophysin/SYP by qPCR.

Endothelial induction {#jcmm13468-sec-0013}
---------------------

CLP‐CMCs (2x10^4^cells/cm^2^) were seeded on 24‐well plates coated with 0.5 ml of Matrigel (diluted 1:10 in standard medium) (BD Bioscience) and cultured in a humid atmosphere with 5% CO~2~. At 3 and 7 days from induction, the gene expression of platelet endothelial cell adhesion molecule/CD31 was analysed by one‐step reverse transcriptase--PCR (Qiagen, Hilden, Germany). In parallel, we evaluated the formation of capillary‐like structures by optical microscopy using an inverted microscope Motic [AE2000](AE2000) (Motic^®^, Wetzlar, Germany) equipped with Nikon DS‐L1 camera (Nikon, Düsseldorf, Germany), and the expression of blood‐clotting protein factor VIII/FVIII by immunofluorescence. Finally, to better explore the endothelial potential of CLP‐CMC cells, extracellular vesicles/exosomes (EVs/exs) were isolated using Cell Culture‐Nanovesicles kit (Biofield Innovation Srl, Padova, Italy) from conditioned media according to the manufacturer\'s protocol. After labelling with PKH26 Red Fluorescent Cell Linker Kit for General Cell Membrane Labeling (Sigma‐Aldrich), all samples were characterized by FCM for size, using as reference polystyrene beads supplied in Flow Cytometry Size Calibration Kit (Molecular Probes, Inc, Eugene, OR), and expression of CD9 or CD63 by indirect staining, according to the Pospichalova protocol [14](#jcmm13468-bib-0014){ref-type="ref"}. Moreover, we analysed by WB the expression of tetraspanin family protein/CD9, FVIII, Wnt3a ligand. Extracellular vesicles/exosomes from resting cells were considered as reference. For excluding cells from the analysis, cis‐Golgi marker/GM‐130 was considered as staining control. All antibodies used are listed in Table [2](#jcmm13468-tbl-0002){ref-type="table-wrap"}.

Statistical analysis {#jcmm13468-sec-0014}
====================

It was performed with paired Student\'s *t*‐test, and results were considered significant when *P *\<* *0.05.

Results {#jcmm13468-sec-0015}
=======

Isolation and growth of human CPL‐CMC cells {#jcmm13468-sec-0016}
-------------------------------------------

The study included 10 male volunteers under therapy with haemoderivatives for impaired wound healing. After 21 days from seeding, all samples showed an active cell sprouting with spindle‐ or flat‐like shaped cells at early‐phase and cells with fibroblastic morphology at late‐phase (Fig. [1](#jcmm13468-fig-0001){ref-type="fig"}A). Accordingly, a different expression pattern of the inflammatory cytokine TNFα and the protective molecule IL‐10 was observed (Fig. [1](#jcmm13468-fig-0001){ref-type="fig"}A), suggesting a possible correlation among *in vivo* regeneration following the implantation of CLP‐MB and the *in vitro* development of cells with anti‐inflammatory functionality, proliferative activity and high grade of stemness. In particular, CPL‐CMC subcultures from 4th to 20th generation demonstrated a doubling population time of 21 ± 1.85 hrs, which was significantly shorter than that of other multipotent cells [12](#jcmm13468-bib-0012){ref-type="ref"}, [13](#jcmm13468-bib-0013){ref-type="ref"} isolated from human peripheral blood (Fig. [1](#jcmm13468-fig-0001){ref-type="fig"}B). During *in vitro* short and prolonged expansion, a high positive expression of transcription factors NANOG, SOX2, KLF4, STAT3 was detected (Fig. [1](#jcmm13468-fig-0001){ref-type="fig"}C), suggesting a high stemness grade of CPL‐CMCs. In parallel, normal karyotype of 46 chromosomes with no aneuploidy, tetraploidy or other visible abnormalities was verified (data not shown).

![Compared to other blood‐derived stem cell populations, CLP‐CMCs have a distinctive stemness signature. Morphological study and stemness characterization of human CLP‐CMCs. (**A**) Optical microscopy image of CLP‐MB and CLP‐CMC sprouted cells at early and late‐phases during 21 days of *in vitro* culturing. Scale bar: 25 μm. (**B**) Calculation of doubling population time (DPT) over a total of 16 divisions. (**C**) Gene expression analysis of pluripotency markers by quantitative PCR in cells grown in proliferative medium. The comparative CT method (2^−ΔCt^ ± S.D) was used to quantify the gene expression level. *HPRT* was considered as housekeeping gene.](JCMM-22-1840-g001){#jcmm13468-fig-0001}

Multipotency of CPL‐CMCs {#jcmm13468-sec-0017}
------------------------

By FACS analysis, the immunophenotypic profile of CMC was determined (Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}). Interestingly, all populations extracted from CPL membranes showed an almost homogenous expression of CD44/HCELL, CD49f and CD184/CXCR4 (Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}A) that are markers related to bone marrow derivation [15](#jcmm13468-bib-0015){ref-type="ref"}, multipotency [16](#jcmm13468-bib-0016){ref-type="ref"} and migratory potentialities [17](#jcmm13468-bib-0017){ref-type="ref"}. As expected, several markers typically expressed in multipotent stem cells or mediating transendothelial migration, angiogenic potentiality, cell--matrix and cell--cell interactions, and finally immune properties were detected in CPL‐CMCs. They included CD13, CD73, CD105, SSEA4, NG2 as stem cell markers; CD106, CD144, CD146, CD166, von Willebrand factor/vWF as endothelial stem/progenitor phenotype cues; and CD11b, CD18, CD103 as adhesion molecules (Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}B). Glycolipids [18](#jcmm13468-bib-0018){ref-type="ref"}, such as NG2, and heparan sulphate proteoglycans [19](#jcmm13468-bib-0019){ref-type="ref"}, such as syndecan‐1/SDC1 [20](#jcmm13468-bib-0020){ref-type="ref"}, [21](#jcmm13468-bib-0021){ref-type="ref"} and perlecan/PLC [21](#jcmm13468-bib-0021){ref-type="ref"}, are critical environmental regulators of haematopoietic and mesenchymal stem cell niches. As reported in Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}B, CPL‐CMC cells showed to express SDC1 and PLC that, together with CD34 and CD38, were assumed as indicative of both adhesive properties to endothelium and possible derivation from bone marrow. Other markers such as CD14, CD29, CD31, CD45, CD90, CD117, CD133, PDGFRβ were not detected (Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}B). Moreover, CPL‐CMCs demonstrated by FCM to possess immune properties and engraftment potential expressing tetraspanin CD9 [22](#jcmm13468-bib-0022){ref-type="ref"}, TGFβ [23](#jcmm13468-bib-0023){ref-type="ref"} and SIRPα [24](#jcmm13468-bib-0024){ref-type="ref"} (Fig. [2](#jcmm13468-fig-0002){ref-type="fig"}B). For CD9, a role in migration, adhesion and homing is also considered [25](#jcmm13468-bib-0025){ref-type="ref"}, [26](#jcmm13468-bib-0026){ref-type="ref"}. The null expression of HLA Class II and the low level of HLA Class I confirmed the potentialities of CPL‐CMCs for both allogeneic and autologous therapies [27](#jcmm13468-bib-0027){ref-type="ref"}. Taken together, our collected data demonstrated distinctive immunophenotypic properties of CPL‐CMCs as compared to other blood‐derived stem cell populations.

![CLP‐CMCs proliferate *in vitro* without reaching replicative senescence and growth arrest. FCM characterization of CLP‐CMC subcultures under proliferative conditions. Data are reported as mean percentage of positive cells and relative mean fluorescence intensity (MFI) calculated on *n *=* *3 replicas of each sample for all target markers. Samples treated with only secondary antibodies or isotype control antibodies were used as references.](JCMM-22-1840-g002){#jcmm13468-fig-0002}

Responsiveness of CPL‐CMC cells to environmental stimuli {#jcmm13468-sec-0018}
--------------------------------------------------------

As reported in Fig. [3](#jcmm13468-fig-0003){ref-type="fig"}A, CPL‐CMCs showed by WB the expression of numerous growth factors, including EGF, FGF, neurotrophins and Wnt ligands. The synthesis of pro‐ and anti‐inflammatory cytokines (Fig. [3](#jcmm13468-fig-0003){ref-type="fig"}B), receptors of TNFα (Fig. [3](#jcmm13468-fig-0003){ref-type="fig"}B) and matrix remodelling enzymes such as MMP‐2, MMP‐9 and MM‐P13 (Fig. [3](#jcmm13468-fig-0003){ref-type="fig"}C) was detected at mRNA level.

![High responsivity to Wnt signals, growth factors, neurotrophins and potential migratory activity are observed in CLP‐CMCs. (**A**) Evaluation of CLP‐CMC responsivity to environmental stimuli by FCM. (**B**) Gene expression analysis of immune properties and matrix remodelling enzymes by qPCR.](JCMM-22-1840-g003){#jcmm13468-fig-0003}

Differentiative potentialities of CPL‐CMCs {#jcmm13468-sec-0019}
------------------------------------------

After specific differentiation induction, the plasticity of CMCs towards adipogenic, myogenic and neurogenic lineages was demonstrated evaluating the gene expression of lineage‐specific markers (Fig. [4](#jcmm13468-fig-0004){ref-type="fig"}A, Fig. [5](#jcmm13468-fig-0005){ref-type="fig"}A, Fig. [6](#jcmm13468-fig-0006){ref-type="fig"}A), the accumulation of lipid droplets (Fig. [4](#jcmm13468-fig-0004){ref-type="fig"}B), the acquisition of cell‐orientated distribution (Fig. [5](#jcmm13468-fig-0005){ref-type="fig"}B) and the assembling of cytoskeleton components (Fig. [6](#jcmm13468-fig-0006){ref-type="fig"}B). CPL‐CMCs displayed the gene expression of CD31 (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}A), an increased protein expression of CD166 and vWF (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}B) and the formation of capillary‐like network structures (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}C). The acquired endothelial‐like phenotype was furtherly confirmed by the protein expression of FVIII together with EGF and vWF, in CD9‐tagged mixed population of extracellular vesicles and exosomes (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}D). In parallel, resting cells cultured on polystyrene culture dishes showed elongated morphology at maximum confluence (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}C) and expressed Wnt3a by Evs/exs (Fig. [7](#jcmm13468-fig-0007){ref-type="fig"}D).

![Under permissive *in vitro* conditions, CLP‐CMCs acquire adipocyte‐like phenotype. (**A**) Gene expression analysis of perilipin/PLIN1 and leptin/LEP. (**B**) Detection of cytoplasmic lipid droplets by Oil Red O staining. Nuclei were counterstained with haematoxylin. Scale bar: 25 μm.](JCMM-22-1840-g004){#jcmm13468-fig-0004}

![CLP‐CMCs have a potential to undergo myogenic‐like commitment. (**A**) qPCR analysis of MYOD1, myogenin/MYOG) and tropomyosin/TPM1. (**B**) Immunofluorescence detection of vimentin. Nuclei were counterstained with Fluoro‐Gel II solution containing DAPI. Scale bar: 25 μm.](JCMM-22-1840-g005){#jcmm13468-fig-0005}

![Neurogenic differentiative ability of CLP‐CMCs is demonstrated *in vitro*. (**A**) qPCR analysis of ß‐tubulin isotype III/TUBB3, synaptophysin/SYP and neuronal nuclear antigen RBFOX3/NEUN). (**B**) Immunofluorescence detection of TUBB3. Nuclei were counterstained with Fluoro‐Gel II solution containing DAPI. Scale bar: 10 μm.](JCMM-22-1840-g006){#jcmm13468-fig-0006}

![In comparison with resting cells (−), CLP‐CMCs respond to the stimulation with BD Matrigel^TM^ (+) acquiring endothelial‐like phenotype. (**A**) Analysis of CD31 gene by *one‐step* RT‐PCR. (**B**) WB analysis of vascular adhesion molecules (CD18, CD106, CD166), vWF and GAPDH housekeeping protein. (**C**) Optical microscopy (*left side)* and immunofluorescence (*right side*) detecting FVIII in cells counterstained with DAPI. Scale bar: 25 μm. (**D**) FCM characterization of PKH26‐tagged extracellular vesicles/exosomes \[isolated from the conditioned culture media of CLP‐CMCs stimulated with BD Matrigel^TM^ (+) or resting cells (−). The vesicles were discriminated by size, using polystyrene beads as reference, and by expression of characteristic markers, CD9 and CD63. (**E**) WB analysis of FVIII,WNT3a, EGF,vWF,CD9 in extracellular vesicles/exosomes isolated from the conditioned culture media of CLP‐CMCs stimulated with BD Matrigel^TM^ (+) or resting cells (−). To verify the absence of cells, the expression of cis‐Golgi marker/GM‐130 was considered as negative control.](JCMM-22-1840-g007){#jcmm13468-fig-0007}

Discussion {#jcmm13468-sec-0020}
==========

Offering the cellular, physical and chemical cues implicated in haemostatic response and tissue restoration, the haemoderivatives show great potentials for regenerative medicine [28](#jcmm13468-bib-0028){ref-type="ref"}.

Opening new perspectives in autologous stem cell research, L‐PRF products prepared according to Caloprisco\'s method [10](#jcmm13468-bib-0010){ref-type="ref"} have been found to deliver stem cell‐like cells with unique phenotypic features, functionality and differentiative potentialities in comparison with endothelial/haematopoietic progenitors [29](#jcmm13468-bib-0029){ref-type="ref"}, [30](#jcmm13468-bib-0030){ref-type="ref"}, mesenchymal stem cells (MSCs) [27](#jcmm13468-bib-0027){ref-type="ref"}, [31](#jcmm13468-bib-0031){ref-type="ref"}, [32](#jcmm13468-bib-0032){ref-type="ref"}, embryonic‐like stem cells [11](#jcmm13468-bib-0011){ref-type="ref"}, [33](#jcmm13468-bib-0033){ref-type="ref"}, [34](#jcmm13468-bib-0034){ref-type="ref"}, [35](#jcmm13468-bib-0035){ref-type="ref"}, [36](#jcmm13468-bib-0036){ref-type="ref"} and circulating multipotent cells [12](#jcmm13468-bib-0012){ref-type="ref"}, [13](#jcmm13468-bib-0013){ref-type="ref"}, [25](#jcmm13468-bib-0025){ref-type="ref"}, [37](#jcmm13468-bib-0037){ref-type="ref"}. Isolated by minimal *in vitro* manipulation of CPL membranes, CMC cells showed fibroblast‐like morphology, long‐lasting proliferative activity and high expression of CD44/HCELL, CD49f and CXCR4. The overlapping expression of embryonic (SSEA‐4), mesenchymal (CD13, CD105, CD106, CD73, CD146), haematopoietic (CD38, CD34) and endothelial (CD144, CD166, vWF) stem cell markers highlighted the presence of distinct immature subsets. Moreover, specific immunomodulatory (CD9, SIRPα, pro‐ and anti‐inflammatory cytokines) properties and receptors for Wnt ligands (FZD1/2/3/9), growth factors (EGFR, FGFR2, p75, VEGFR2) and inflammatory stimuli (TNFR1/2) confirmed high environmental responsiveness of CPL‐CMCs. Lacking integrin β1, CD90 and PDGFRβ, CMC cells showed distinct immunophenotype and origin in comparison with circulating multipotent progenitor cells [12](#jcmm13468-bib-0012){ref-type="ref"}, [38](#jcmm13468-bib-0038){ref-type="ref"} and perivascular multipotent progenitor cells [22](#jcmm13468-bib-0022){ref-type="ref"}, [39](#jcmm13468-bib-0039){ref-type="ref"}. Primed by the interaction with fibrin matrix and P‐selectins on activated platelets [40](#jcmm13468-bib-0040){ref-type="ref"}, [41](#jcmm13468-bib-0041){ref-type="ref"}, the immunophenotypic heterogeneity of CPL‐CMCs has been suggested to reflect a dynamic equilibrium between the acquired responsivity to extracellular signals and the retained self‐renewal potential [42](#jcmm13468-bib-0042){ref-type="ref"}. Based on the expression profile of adhesion molecules (CAMs) and glycolipids/proteoglycans, the physiological and regulatory processes underlying the trafficking of CLP‐CMCs in peripheral blood were defined as similar to those of leucocytes.

Likely haematopoietic stem and progenitor cells, CLP‐CMCs displayed the specialized glycoform of CD44 known as HCELL, suggesting to have a possible haematopoietic origin, bone marrow derivation and transendothelial migration potential. As reported by Sackstein [15](#jcmm13468-bib-0015){ref-type="ref"}, the cell migration from vascular to extravascular compartments develops by two different mechanisms: the canonical multistep process and the so‐called step 2‐bypass pathway. In the canonical pathway, following the initial tethering/rolling contact of blood‐borne cells with endothelium, CXCR4 binds to its cognate ligand CXCL1/SDF‐1, thereby triggering G protein‐coupled VLA‐4 activation, with subsequent firm adhesion and transmigration. In the 'step 2‐bypass pathway', the activation of VLA‐4 occurs *via* G protein‐mediated mechanosignaling after HCELL binding to E‐selectin and/or CD44 interaction with endothelial HA. As suggested by the intracellular expression of CXCR4, the extravasation of CPL‐CMCs is likely to progress by the canonical pathway.

The stemness signature of CPL‐CMCs was further confirmed by both the gene expression of the key components of self‐renewal machinery (NANOG, SOX2, KLF4, STAT3) [43](#jcmm13468-bib-0043){ref-type="ref"}, [44](#jcmm13468-bib-0044){ref-type="ref"}, [45](#jcmm13468-bib-0045){ref-type="ref"} and the almost homogenous expression of CD49f [46](#jcmm13468-bib-0046){ref-type="ref"}, that is known for transducing survival signals, mediating endothelial progenitor cell migration/adhesion and enhancing multipotency through OCT4, SOX2 and NANOG [12](#jcmm13468-bib-0012){ref-type="ref"}, [43](#jcmm13468-bib-0043){ref-type="ref"}. Collectively, our data pointed out that the self‐renewal of CPL‐CMCs could be regulated likely in embryonic stem cells wherein KLF4 connects STAT3 activation with NANOG expression after interacting with SOX2 and OCT4 [45](#jcmm13468-bib-0045){ref-type="ref"}.

A growing body of evidence suggests that L‐PRF products, including CPL‐MB, are attractive biomaterials for regenerative medicine due to their ability to promote *in vivo* a guided tissue regeneration by 'endogenous cell homing'. Our findings add a novel aspect to the complex picture of stem cell research demonstrating that CPL‐MB functions as a reservoir of autologous stem cells that could be isolated under permissive conditions by culturing *ex vivo* the haemoderivatives. Currently, apart from HSC transplantation for haematologic diseases, the clinical experience with somatic stem cell therapy appears promising but still restricted by biological questions about the safety of cell manufacturing, the route of administration, the irreversibility of treatment and the not predictable long‐term survival of engrafted cells [47](#jcmm13468-bib-0047){ref-type="ref"}, [48](#jcmm13468-bib-0048){ref-type="ref"}. Due to these limitations, and considering that, during *in vitro* expansion of multipotent stem cells, the homing molecules could be lost causing a significant reduction in cell migratory efficiency [49](#jcmm13468-bib-0049){ref-type="ref"}, [50](#jcmm13468-bib-0050){ref-type="ref"}, [51](#jcmm13468-bib-0051){ref-type="ref"}, circulating endogenous stem/progenitor cells could represent a valid and alternative source of immature cells for medical autologous applications [52](#jcmm13468-bib-0052){ref-type="ref"}. Responding to a temporally defined sequence of instructive cues mostly derived from platelets, haematopoietic and not haematopoietic cells from CPL membranes shape a co‐ordinated progression from inflammation to regenerative‐like phases, mimicking the response of living tissues to injury [53](#jcmm13468-bib-0053){ref-type="ref"}, [54](#jcmm13468-bib-0054){ref-type="ref"}, [55](#jcmm13468-bib-0055){ref-type="ref"}, [56](#jcmm13468-bib-0056){ref-type="ref"}. One of the key findings of our study was the recognition of CLP‐CMCs as cells expressing striking morphological and immunophenotypic similarities to alternatively activated M2 macrophages [57](#jcmm13468-bib-0057){ref-type="ref"} and myeloid angiogenic cells (MACs) [58](#jcmm13468-bib-0058){ref-type="ref"}. Showing an elongated/spindle shape and the expression of mannose receptor/CD206, IL‐10, TGFβ1 and Wnt3a [59](#jcmm13468-bib-0059){ref-type="ref"}, [60](#jcmm13468-bib-0060){ref-type="ref"}, CPL‐CMC cells have been suggested to function by dampening inflammatory responses, scavenging cellular debris and promoting angiogenesis. Furthermore, the engagement of CD206 signalling could be also involved in the cell trafficking of CPL‐CMCs through the stimulated production of MMPs (*i.e*. MMP‐2, MMP‐9) and matrix remodelling [61](#jcmm13468-bib-0061){ref-type="ref"}. Indeed, in the early‐phase of *in vitro* culture, CPL membranes showed a significant cell sprouting, thus indirectly suggesting that a proteolytic activity and fibrinolysis were active. The fibrinolytic system, with its main player plasmin, plays a crucial role in cell migration, bioavailability of growth factors and regulation of other protease systems during inflammation and tissue regeneration [28](#jcmm13468-bib-0028){ref-type="ref"}, [62](#jcmm13468-bib-0062){ref-type="ref"}. As the internalization and the degradation of plasminogen activator require the mannose receptor [63](#jcmm13468-bib-0063){ref-type="ref"}, it is likely that CPL‐CMCs could modulate the process of fibrinolysis within CPL membranes for regulating their proliferation, differentiation [62](#jcmm13468-bib-0062){ref-type="ref"}, [64](#jcmm13468-bib-0064){ref-type="ref"}, [65](#jcmm13468-bib-0065){ref-type="ref"} and migration [61](#jcmm13468-bib-0061){ref-type="ref"}.

Finally, based on their abilities to respond to differentiative stimuli, a broad range of medical applications of CLP‐CMCs could have been suggested, including the treatment of (*i*) blood disorders, such as haemophilia [66](#jcmm13468-bib-0066){ref-type="ref"}; and (*ii*) defects of adipose tissue, skeletal muscle and nervous system [67](#jcmm13468-bib-0067){ref-type="ref"}.

Conclusion {#jcmm13468-sec-0021}
==========

As a direct evolution of fibrin glue technologies, autologous platelet preparations are a new generation of biomaterials used in regenerative medicine for improving tissue healing. In this study, we demonstrated that the leucocyte‐ and platelet‐rich fibrin product called CPL‐MB functions not only as a reservoir of bioactive factors (PDGF, TGF‐β, VEGF, fibrinogen, fibronectin and vitronectin), useful to recruit stem cells to wound site, but acts also as an artificial stem cell niche containing haematopoietic and multipotent cells, similarly to bone marrow and perivascular niches. Our *in vitro* model provides the first evidence that multipotent cells could be mobilized to peripheral blood under physiological conditions and not only under stress conditions (*i.e*. inflammation, tissue damage, stimulation by drugs or growth factors), as commonly reported. Likely the haematopoietic stem cell niche, CPL‐MB results as a complex milieu that regulates, by structural and bioactive factors, the survival, expansion, differentiation and transendothelial migration of immature cells. Although a growing body of evidence suggests the existence of multipotent cells in peripheral blood, to date, the use of blood as an alternative source of autologous stem cells in regenerative medicine is limited by several important questions concerning the predictability of successful isolation and *ex vivo* expansion by a standardized protocol. Produced according to Italian standards of quality assurance and Caloprisco\'s method, CPL‐MB could represent a valid strategy to bypass the intrinsic heterogeneity of blood samples and to normalize the cell content of blood derivatives for obtaining autologous cells with a defined stemness signature.
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